A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 30, 2017

Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan

TOKYO & CAMBRIDGE, Mass., Jan. 30, 2017 — Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today top-line results indicating that the Phase III...

Read more about Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Jan 18, 2017

Astellas Announces Participation in Access Accelerated - Builds on Company Commitment to improve Access to Health -

Tokyo, January 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced its participation in Access Accelerated, a global, multi-stakeholder...

Read more about Astellas Announces Participation in Access Accelerated - Builds on Company Commitment to improve Access to Health -
Jan 12, 2017

Astellas Launches Second Phase of Global Campaign on CNN

Tokyo, January 12, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the second phase of the ongoing campaign with CNN....

Read more about Astellas Launches Second Phase of Global Campaign on CNN
Jan 10, 2017

Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of...

Read more about Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs
Dec 26, 2016

Notice of Completion of Acquisition of Own Shares

Tokyo, December 26, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of...

Read more about Notice of Completion of Acquisition of Own Shares
Dec 21, 2016

Astellas Completes Acquisition of Ganymed Pharmaceuticals

Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals...

Read more about Astellas Completes Acquisition of Ganymed Pharmaceuticals
Dec 20, 2016

AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN

TOKYO (Dec. 20, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN
Dec 20, 2016

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy

Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic...

Read more about Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
Dec 19, 2016

Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -

Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C)...

Read more about Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -
Dec 15, 2016

Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo,...

Read more about Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells
Dec 14, 2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer

Read more about Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer
Dec 12, 2016

Astellas Announces Transfer of Qutenza to Grünenthal

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma...

Read more about Astellas Announces Transfer of Qutenza to Grünenthal
Dec 8, 2016

Astellas Research & Development Meeting Highlights

- Turning Innovative Science into Value for Patients -

Read more about Astellas Research & Development Meeting Highlights
Dec 7, 2016

Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, December 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched Kiklin® Granules 86.2% (generic name: bixalomer,...

Read more about Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
Dec 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Nov 30, 2016

Initiatives to Pursue Operational Excellence

Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged...

Read more about Initiatives to Pursue Operational Excellence
Nov 18, 2016

Antihypertensive Drug "Micatrio® Combination Tablets"

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...

Read more about Antihypertensive Drug "Micatrio® Combination Tablets"
Nov 11, 2016

Astellas Transfers Its Global Dermatology Business to LEO Pharma

Read more about Astellas Transfers Its Global Dermatology Business to LEO Pharma
Nov 9, 2016

GUINNESS WORLD RECORDSTM Title Achieved for Organ Donor Registrations

Astellas, Donate Life America and World Transplant Games Federation Celebrate Achievements for Global Transplant Community at History-making Rugby Match

TOKYO and CHICAGO, Ill. – Nov. 9 2016 – Astellas Pharma Inc. (TSE: 4503, collectively with its subsidiaries “Astellas”), Donate Life America and the World Transplant Games Federation today...

Read more about GUINNESS WORLD RECORDSTM Title Achieved for Organ Donor Registrations
Nov 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Oct 30, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Oct 28, 2016

Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -

Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a...

Read more about Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -
Oct 28, 2016

Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year Outlook

Read more about Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year Outlook
Oct 28, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Oct 21, 2016

FDA Approves Supplemental New Drug Application for XTANDI in Advanced Prostate Cancer

TOKYO and NEW YORK, Oct. 21, 2016 -- Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...

Read more about FDA Approves Supplemental New Drug Application for XTANDI in Advanced Prostate Cancer
Oct 20, 2016

Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity -Sponsors CNN Heroes Starting October 20 -

Tokyo, October 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the newest element in its global corporate brand campaign...

Read more about Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity -Sponsors CNN Heroes Starting October 20 -
Oct 19, 2016

Termination of Business Transfer Discussion with Kaketsuken

Tokyo, October 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the...

Read more about Termination of Business Transfer Discussion with Kaketsuken
Oct 14, 2016

World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports

MONTREAL and TOKYO, 14 October 2016 – The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka,...

Read more about World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
Oct 13, 2016

FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

North Brunswick, N.J. and Tokyo, October, 12, 2016 – Chromocell Corporation and Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Read more about FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care

Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care
Oct 7, 2016

Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States

Tokyo, Japan, October 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) and its subsidiaries jointly filed a lawsuit against Actavis Elizabeth LLC...

Read more about Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States
Oct 5, 2016

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Tokyo, October 5, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the "Flying Star Fund," a social contribution fund run by its employees,...

Read more about Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
Sep 28, 2016

Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

Osaka and Tokyo (Japan), September 28, 2016 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office:...

Read more about Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area
Sep 28, 2016

Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 28, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it received a marketing approval of Kiklin® Granules 86.2%...

Read more about Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
Sep 28, 2016

Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...

Read more about Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-
Sep 19, 2016

Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients

SAN DIEGO and TOKYO - September 19, 2016 – Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced topline results from a randomized, double-blind,...

Read more about Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
Sep 16, 2016

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index...

Read more about Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year
Sep 7, 2016

Astellas donates ambulances on First Aid Day (September 9)

Tokyo, September 7, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it will donate three high-standard ambulances on First Aid Day...

Read more about Astellas donates ambulances on First Aid Day (September 9)
Aug 23, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Aug 19, 2016

Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transplant Recipients Worldwide

HONG KONG August 19, 2016 -- Astellas Pharma Inc. (TSE: 4503, “Astellas”) and the World Transplant Games Federation (WTGF) today announced the launch of Fit for Life!, a global program to help...

Read more about Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transplant Recipients Worldwide
Aug 9, 2016

Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan

Tokyo, August 9, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application to the Ministry of Health,...

Read more about Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan
Aug 4, 2016

Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara

Read more about Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara
Jul 29, 2016

Astellas Reports First Quarter Financial Results of FY2016

Read more about Astellas Reports First Quarter Financial Results of FY2016
Jul 29, 2016

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital

Tokyo and San Francisco, July 29, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce...

Read more about Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital
Jul 27, 2016

CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS

Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option

SOUTH SAN FRANCISCO, Calif. and TOKYO, Japan, July 27, 2016 – Cytokinetics, Inc. (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that...

Read more about CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS
Jul 25, 2016

Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan

Read more about Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
Jul 6, 2016

Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year

Tokyo, July 6, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year
Jun 23, 2016

The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine

Tokyo, June 23, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...

Read more about The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine
Jun 2, 2016

ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Read more about ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts